MYONYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesUS GAAP · USD

Myomo Inc

Myomo, Inc. is a U.S.-based wearable medical robotics company that develops and markets the MyoPro line of custom-fabricated myoelectric upper-limb braces. Its devices are designed to help adults and adolescents with neuromuscular disorders or paralysis regain functional use of a weak or paralyzed arm in daily activities.

Kysy yhtiöstä
Liikevaihto40,9milj. USD
+25,7 %v/v
Liikevoitto (EBIT)−14,4milj. USD
−132,0 %v/v
EBIT-marginaali−35,2%
−16,1 %-yks.v/v
Nettotulos−15,6milj. USD
−151,9 %v/v
Vapaa kassavirta−16,3milj. USD
−249,5 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−200204060milj. USD2020: 7,6 milj. USD2020: EBIT −11 milj. USD20202021: 14 milj. USD2021: EBIT −10 milj. USD20212022: 16 milj. USD2022: EBIT −11 milj. USD20222023: 19 milj. USD2023: EBIT −8,2 milj. USD20232024: 33 milj. USD2024: EBIT −6,2 milj. USD20242025: 41 milj. USD2025: EBIT −14 milj. USD202541−14
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Myomo Inc

Liiketoiminta

Osuus liikevaihdosta
MyoPro devices85 %

Custom-fabricated myoelectric upper-limb braces that support weak or paralyzed arms and enable ADLs.

Direct billing channel services10 %

Patient evaluation, fitting, reimbursement processing and insurance billing tied to direct-to-patient sales.

O&P provider channel5 %

Sales and clinical support delivered through orthotics and prosthetics providers in the U.S. and abroad.

Asiakkaat

Myomo sells primarily to patients with neuromuscular disorders and upper-limb paralysis, but the economic buyer is often an insurer or government health plan that reimburses the device. It also serves orthotics and prosthetics providers, the Veterans Administration, and rehabilitation hospitals that fit or recommend the product for eligible patients. Internationally, the company works with O&P providers and distributors in selected markets where regulatory approvals and reimbursement pathways exist.

Direct-to-patient reimbursement pipeline

Patients evaluated and fitted by Myomo or its clinical staff, with insurance authorization driving revenue recognition.

Medicare Part B beneficiaries

Patients served at published CMS fees, an important source of volume and faster revenue conversion.

Orthotics and prosthetics providers

O&P practices that market, fit and support MyoPro devices, especially in the U.S. and Germany.

Veterans Administration

VA-related sales for eligible veterans who need upper-limb functional assistance.

International patients and providers

Customers in Europe, Canada and Australia served through regulatory approvals and local provider relationships.

Strategia

Myomo is focused on expanding recurring revenue sources, especially through its MyoConnect referral program and a larger U.S. O&P channel. It is also investing in direct-billing capacity, advertising, clinical headcount and manufacturing support to shorten cycle times and convert more patients into revenue. Product development remains important, highlighted by the launch of MyoPro 2X and continued R&D spending to support new and sustaining products.

Expand direct billing and patient acquisition efficiencyLyhyt aikaväli

Direct billing is the largest revenue channel, so lower acquisition cost and faster conversion improve scale and cash generation.

Build the U.S. O&P channelKeskipitkä aikaväli

O&P providers can broaden reach and reduce dependence on advertising-driven direct-to-patient demand.

Expand recurring referral sourcesKeskipitkä aikaväli

Referrals from rehab clinics and stroke centers can create a steadier patient pipeline and improve operating leverage.

Develop and launch improved productsKeskipitkä aikaväli

Newer devices can support pricing, clinical differentiation and competitive defense.

Maantiede

Myomo is headquartered in the United States and generates most revenue there through direct billing, Medicare and U.S. O&P channels. It also sells in Europe, Canada and Australia, and has specifically highlighted Germany as an important international market. The company has obtained EU market access for MyoPro, a Canadian medical device license, and provider agreements in the U.K., Denmark, Germany, Italy and Australia, while its China joint venture has been disrupted by partner bankruptcy.

Riskit

Myomo depends on reimbursement approvals, patient acceptance and a limited set of clinical and supplier relationships, so demand can be volatile and operational disruptions can quickly affect revenue. It also faces intense competition from medical robotics and O&P companies, plus regulatory and intellectual property risk in a niche market where published billing fees may attract new entrants. International expansion adds country-specific reimbursement, partner and geopolitical exposure, including the disruption of its China joint venture.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Reimbursement dependence1Patient adoption and access barriers2Supplier concentration3Competitive pressure4China joint venture disruption5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Reimbursement dependenceVaikutus: KorkeaTodennäköisyys: Korkea

    Revenue recognition and patient demand rely on insurance authorization, Medicare coverage and payer payment behavior.

    KohdistuuU.S. commercial payersMedicare Part BStatutory health plans in Germany
  2. Patient adoption and access barriersVaikutus: KorkeaTodennäköisyys: Korkea

    Patients may resist wearing an external device or face health, social or economic barriers to evaluation and fitting.

    Kohdistuu: Direct-to-patient channel

  3. Supplier concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company depends on a single third party for key subassemblies and limited suppliers for components.

    Kohdistuu: Manufacturing and supply chain

  4. Competitive pressureVaikutus: KeskitasoTodennäköisyys: Korkea

    Competitors can respond with lower-cost or more effective devices, especially after billing fees become public.

    Kohdistuu: U.S. and Germany

  5. China joint venture disruptionVaikutus: KeskitasoTodennäköisyys: Matala

    The Ryzur Medical bankruptcy severely limited JV operations and may reduce expected international expansion value.

    KohdistuuChinaHong KongTaiwanMacau
Kysy Clarifolta: Myomo Inc

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition timing and transaction pricing

Revenue depends on insurance payment estimates and when authorization or documentation is obtained.

Vaikutus: Can materially change quarterly revenue and gross margin

Derivative liabilities

Fair value remeasurement can create non-cash gains or losses.

Vaikutus: Affects reported net loss and earnings volatility

Warranty obligations and reserves

Custom medical devices require estimates for future warranty claims and support costs.

Vaikutus: Affects cost of revenue and gross margin

Inventory and slow-moving reserves

Custom components and new product launches can create obsolescence risk.

Vaikutus: Can reduce gross profit if reserves increase

Stock-based compensation and valuation allowances

Loss-making operations and equity financing can drive significant non-cash charges and tax valuation judgments.

Vaikutus: Affects operating expenses and equity-related disclosures

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Masimo Corp

Electromedical & Electrotherapeutic Apparatus

Lifeward Ltd.

LFWD · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Dynavox Group

DYVOX · Technology

Dyne Therapeutics, Inc.

DYN · Pharmaceutical Preparations

LiveWire Group, Inc.

LVWR · Motorcycles, Bicycles & Parts

Dynatronics Corp

DYNTQ · Surgical & Medical Instruments & Apparatus

Päivitetty: 24.9.2026

Myomo Inc (MYO) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo